Narlaprevir: Proven Effectiveness and Safety
Soon a new drug for hepatitis C Arlansa (narlaprevir) will be available in Russian pharmacies. It is launched by R-Pharm.
It was announced at the III Russian National Research and Practice Conference with International Participation Socially Significant and Highly Infectious Disorders, held in Sochi early in November.
Arlansa (narlaprevir) is a drug with direct antiviral action for treatment of hepatitis C. It is the first authorized Russian HCV NS3 serine protease inhibitor in tablets used in combination with other antiviral drugs. A large-scale program of preclinical and clinical trials in US and European sites has been completed. Besides, largest Russian centers involved in treatment of viral hepatitis participated in the study. Results have shown data on narplaprevir experience in the Russian population of patients with 1b genotype HCV.
The drug development was supported within the Federal Target Program PHARMA-2020 within the contract conditions for transfer of international development and manufacture of the innovative drug, concluded in 2011 between the Ministry of Industry and Trade of the Russian Federation and R-Pharm. According to the above-mentioned contract R-Pharm is responsible for Arlanse (narlaprevir) production transfer to its pharmaceutical complex in the Yaroslavl region.